- Home
- XMTR vs GYRE Comparison
XMTR vs GYRE Comparison
Compare XMTR & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XMTR
- GYRE
- Stock Information
- Founded
- XMTR 2013
- GYRE 2002
- Country
- XMTR United States
- GYRE United States
- Employees
- XMTR N/A
- GYRE N/A
- Industry
- XMTR Industrial Machinery/Components
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- XMTR Technology
- GYRE Health Care
- Exchange
- XMTR Nasdaq
- GYRE Nasdaq
- Market Cap
- XMTR 1.1B
- GYRE 897.1M
- IPO Year
- XMTR 2021
- GYRE N/A
- Fundamental
- Price
- XMTR $33.15
- GYRE $9.07
- Analyst Decision
- XMTR Buy
- GYRE
- Analyst Count
- XMTR 11
- GYRE 0
- Target Price
- XMTR $34.09
- GYRE N/A
- AVG Volume (30 Days)
- XMTR 657.4K
- GYRE 337.8K
- Earning Date
- XMTR 05-06-2025
- GYRE 05-09-2025
- Dividend Yield
- XMTR N/A
- GYRE N/A
- EPS Growth
- XMTR N/A
- GYRE N/A
- EPS
- XMTR N/A
- GYRE 0.02
- Revenue
- XMTR $573,810,000.00
- GYRE $100,643,000.00
- Revenue This Year
- XMTR $21.56
- GYRE $22.01
- Revenue Next Year
- XMTR $17.54
- GYRE $88.14
- P/E Ratio
- XMTR N/A
- GYRE $112.98
- Revenue Growth
- XMTR 19.35
- GYRE N/A
- 52 Week Low
- XMTR $11.08
- GYRE $6.11
- 52 Week High
- XMTR $45.33
- GYRE $19.00
- Technical
- Relative Strength Index (RSI)
- XMTR 59.27
- GYRE 45.78
- Support Level
- XMTR $32.28
- GYRE $9.26
- Resistance Level
- XMTR $35.14
- GYRE $11.61
- Average True Range (ATR)
- XMTR 1.79
- GYRE 1.09
- MACD
- XMTR -0.19
- GYRE -0.21
- Stochastic Oscillator
- XMTR 53.94
- GYRE 28.12
About XMTR Xometry Inc.
Xometry Inc is engaged in providing AI-enabled manufacturing equipment. Its buyers include engineers, product designers, procurement and supply chain personnel, inventors, and business owners. The manufacturing processes offered by the company include CNC Machining, Injection Molding, Urethane Casting, 3D Printing, and Die Casting. The company is organized into two segments referred to as the U.S. and the International. The majority of its revenue is derived from the U.S. segment.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.